okt 18, 2018: 8:30 a.m. - 9:40 a.m.
Results of a Phase II clinical trial presented at the July 2018 Alzheimer Association International Conference suggest that an anti-beta amyloid antibody shows promise in slowing cognitive decline in Alzheimer patients, creating hope, but also refueling the debate regarding assumptions about the biology of neurodegeneration. In a field historically focused on beta-amyloid plaques as primary targets but challenged to demonstrate new approvals, what are alterative hypotheses to neurodegenerative treatment development? This panel brings together investors, scientists, and companies expanding the toolbox of neurodegeneration therapies. Collectively, panelists will not only discuss the relevance of misfolded proteins, but also broaden the conversation to include the role of neuro-inflammation, alternative mechanisms of action, and other therapeutic targets for treating neurodegeneration.